Printer Friendly

IMMUNO RESPONSE TECHNOLOGY AND L'AUTREC MERGE TO FORM IRT HOLDING

 IMMUNO RESPONSE TECHNOLOGY AND L'AUTREC MERGE TO FORM IRT HOLDING
 BERLIN, N.J., April 7 /PRNewswire/ -- George H. Young, chairman and president of Immuno Response Technology, Inc. ("IRT") today announced that the company has been acquired by L'Autrec, Inc. ("LTRC") of Salt Lake City. The combined entity will be known as IRT Holding Corporation, with a public market reported on the National Association of Securities Dealers NASDAQ Electronic Bulletin Board under the designated symbol "IRTD."
 The principals of IRT initiated the merger in an effort to strengthen the company's equity base and enable plans for an aggressive expansion program for primary care physicians that include a clinical diagnostic confirmation provided through a network of clinical allergists and immunologists. In addition, the company and its subsidiary, Advanced Allergy Management, Inc., located in La Jolla, Calif., operate clinical testing laboratories which perform proprietary allergy testing and a range of immunology testing.
 As part of the reorganization, LTRC, a business development corporation, effected a 1 for 4 reverse split in its outstanding shares. The outstanding shares of IRT were converted into a total of 4,807,363 shares of post-split LTRC common shares. IRT, Inc. presently has a total of 5,661,530 shares issued and outstanding, of which 11.04 percent is held by LTRC shareholders and 88.96 percent by IRT Holding Corporation shareholders.
 The record date for implementation of the reorganization will be 5 p.m. on April 10, 1992 and trading in the common stock of IRT Holding Corporation ("IRTD") on a post-split basis will commence at the opening of business on April 13, 1992.
 As a result of the merger, IRT plans to expand its clinical immunology laboratory to have full-service cellular and humoral capabilities. The purpose of such expansion is to provide the pharmaceutical, biotechnology and genetic engineering industries the means to demonstrate that their current developments meet all of the newly established FDA guidelines concerning immunotoxicology. The facility will also engage in the development of novel immunodiagnostic reagents for FDA approval. IRT Holding Corporation proposes to become the leading commercial, certified laboratory to service this emerging industry.
 -0- 4/7/92
 /CONTACT: George H. Young, chairman and president of IRTD, 609-753-9595; or Kenneth Latham of the Latham Group, 215-731-1593, for IRTD/
 (IRTD) CO: Immuno Response Technology, Inc.; L'Autrec, Inc.;
 IRT Holding Corporation ST: New Jersey, Utah IN: MTC SU: TNM


GK-OS -- NY049 -- 5915 04/07/92 15:26 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 7, 1992
Words:403
Previous Article:GUARD AND RESERVE CUTS CONCERN AMVETS
Next Article:LENNAR DECLARES QUARTERLY DIVIDENDS


Related Articles
IMMUNO RESPONSE TECHNOLOGY SIGNS LETTER OF INTENT
IRT CORP. CHARGES FOUR PI SYSTEMS WITH FRAUD, UNFAIR COMPETITION AND THEFT OF INTELLECTUAL PROPERTY
An analysis of incident response teams.
Allergy Immuno Technologies, Inc. is in the Process of Responding To the SEC's Comments on Its Form 10-SB.
WebDialogs Teams With IRT to Deliver Enhanced Online Communication Services for Customer Service Call Center.
IRT Property Company Provides Update on Election Procedure For Merger Consideration.
The theory and practice of item response theory.
endpoint Introduces First Fully Configurable IRT System; PULSE Raises Bar in IRT With Innovative Solutions For Next Generation Clinical Studies.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters